Serum CEA and CYFRA levels in ALK-rearranged NSCLC patients: Correlation with distant metastasis
…, T Shiozawa, N Hizawa, Y Funayama, S Hayashi… - in vivo, 2020 - iv.iiarjournals.org
Aim: To clarify the correlation between serum levels of carcinoembryonic antigen (CEA) and
cytokeratin 19 fragment (CYFRA) and metastasis and survival in anaplastic lymphoma …
cytokeratin 19 fragment (CYFRA) and metastasis and survival in anaplastic lymphoma …
Treatment of patients with non-small-cell lung cancer with uncommon EGFR mutations in clinical practice
…, K Miyazaki, T Kodama, S Hayashi… - Anticancer …, 2020 - ar.iiarjournals.org
Background/Aim: To describe real clinical outcomes in patients with non-small cell lung cancer
who have uncommon epidermal growth factor receptor (EGFR) mutations. Materials and …
who have uncommon epidermal growth factor receptor (EGFR) mutations. Materials and …
Clinicopathological features in elderly ALK-rearranged non-small cell lung cancer patients
…, T Shiozawa, N Hizawa, Y Funayama, S Hayashi… - in vivo, 2020 - iv.iiarjournals.org
Aim: To clarify the clinicopathological features in elderly anaplastic lymphoma kinase (ALK)
rearranged non-small cell lung cancer (NSCLC) patients. Patients and Methods: A …
rearranged non-small cell lung cancer (NSCLC) patients. Patients and Methods: A …
Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI)
…, S Okauchi, N Kikuchi, K Miyazaki, S Hayashi… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: Atezolizumab, an anti-programed death-ligand 1 monoclonal antibody,
targets programed death-ligand 1 expressed on cancer cells and antigen-presenting cells and …
targets programed death-ligand 1 expressed on cancer cells and antigen-presenting cells and …
Real clinical practice in ALK-rearranged NSCLC patients: a retrospective observational study
…, K Miyazaki, T Yamashita, S Hayashi… - Anticancer …, 2020 - ar.iiarjournals.org
Background/Aim: To describe real clinical outcomes when using systemic therapy to treat
non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) …
non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) …
Transcription factor T-bet attenuates the development of elastase-induced emphysema in mice
S Hayashi, Y Matsuno, Y Tsunoda… - American Journal of …, 2019 - atsjournals.org
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized
by peripheral airways inflammation and emphysema. Emerging evidence indicates a …
by peripheral airways inflammation and emphysema. Emerging evidence indicates a …
Atezolizumab Monotherapy for Non-small Cell Lung Cancer Patients: An Observational Study in Ibaraki Group (ATTENTION-IBARAKI)
…, T Tamura, N Kikuchi, K Miyazaki, S Hayashi… - in vivo, 2023 - iv.iiarjournals.org
Background/Aim: Atezolizumab is a monoclonal antibody that targets programmed death-ligand
1 (PD-L1) expressed on cancer cells derived from various organs and antigen-…
1 (PD-L1) expressed on cancer cells derived from various organs and antigen-…
Has2 deficiency enhances OVA‐induced airway inflammation and hyperresponsiveness in mice.
…, M Matsuyama, H Osawa, H Sakurai, S Hayashi… - Allergy, 2021 - search.ebscohost.com
Has2 deficiency enhances OVA-induced airway inflammation and hyperresponsiveness in
mice In conclusion, we demonstrated that the attenuation of I Has2 i expression enhances …
mice In conclusion, we demonstrated that the attenuation of I Has2 i expression enhances …
[HTML][HTML] Atypical Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in an Elderly Lung Cancer Patient
G Ohara, M Uchiyama, H Sakurai, S Saito, S Hayashi… - Maedica, 2023 - ncbi.nlm.nih.gov
Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome develops
in patients with various underlying diseases. The involvement of vascular endothelial …
in patients with various underlying diseases. The involvement of vascular endothelial …
[HTML][HTML] Long-term Progression-free Survival With Pemetrexed Plus Bevacizumab in NSCLC Patients
S Hayashi, K Miyazaki, T Shiozawa… - Cancer Diagnosis & …, 2023 - ncbi.nlm.nih.gov
Background/Aim: Pemetrexed (PEM) and bevacizumab (BEV) are commonly used in combination
as second or subsequent line regimens and maintenance therapy after platinum+ PEM…
as second or subsequent line regimens and maintenance therapy after platinum+ PEM…